urinary bladder cancer (Cancer)
Information
- Disease name
- urinary bladder cancer
- Disease ID
- DOID:11054
- Description
- "An urinary system cancer that results_in malignant growth located_in the urinary bladder." [url:http\://en.wikipedia.org/wiki/Bladder_cancer]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03132922 | Active, not recruiting | Phase 1 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | May 15, 2017 | September 2032 |
| NCT03998579 | Completed | N/A | Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer | September 1, 2019 | June 20, 2023 |
| NCT04635566 | Completed | N/A | Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute | March 1, 2019 | March 1, 2020 |
| NCT06156787 | Completed | Patterns of Urinary Bladder Cancer in Darfur, Suda | November 1, 2020 | April 10, 2022 | |
| NCT01836978 | Completed | N/A | Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy | June 2013 | December 2017 |
| NCT02139371 | Completed | Early Phase 1 | Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography | May 2014 | October 2014 |
| NCT02437539 | Completed | Phase 1 | Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography | May 2015 | August 2015 |
| NCT02720367 | Completed | Phase 1 | Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer | January 2016 | March 2020 |
| NCT02722538 | Completed | Phase 1 | Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer | May 31, 2016 | May 2, 2019 |
| NCT02897765 | Completed | Phase 1 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | October 2016 | May 2020 |
| NCT05946369 | Completed | Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer | May 1, 2020 | May 1, 2023 | |
| NCT03433924 | Completed | An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients. | May 18, 2020 | March 27, 2023 | |
| NCT03636256 | Completed | Phase 1/Phase 2 | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | April 2, 2019 | November 2, 2021 |
| NCT00462488 | Completed | Phase 2 | Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | March 2007 | October 2009 |
| NCT05787938 | Not yet recruiting | Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection | April 1, 2023 | December 1, 2024 | |
| NCT06307704 | Recruiting | N/A | Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients | April 1, 2024 | October 2024 |
| NCT00872495 | Recruiting | Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer | September 2002 | November 2025 | |
| NCT03844256 | Recruiting | Phase 1/Phase 2 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study | January 7, 2019 | July 2026 |
| NCT04861584 | Recruiting | Phase 2 | Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | June 3, 2021 | April 3, 2025 |
| NCT04977453 | Recruiting | Phase 1/Phase 2 | GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | August 2, 2021 | October 2026 |
| NCT05072600 | Recruiting | Phase 2 | Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer | December 7, 2021 | November 1, 2029 |
| NCT05621837 | Recruiting | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy | March 10, 2022 | May 17, 2024 | |
| NCT05644041 | Recruiting | Phase 2 | Intravesical Gemcitabine in Patients With NMIBC | March 1, 2023 | January 31, 2025 |
| NCT05822934 | Recruiting | Phase 3 | Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer | November 1, 2022 | December 30, 2023 |
| NCT06115434 | Recruiting | Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy | January 30, 2015 | December 31, 2024 | |
| NCT03335059 | Terminated | Phase 3 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. | April 4, 2019 | February 26, 2020 |
| NCT00384891 | Terminated | Phase 3 | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | February 2002 | December 2013 |
| NCT01374789 | Terminated | Phase 2 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer | July 2010 | March 2012 |
| NCT04812145 | Unknown status | Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma | April 1, 2021 | April 1, 2023 | |
| NCT03529890 | Unknown status | Phase 2 | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder | February 4, 2019 | August 2023 |
| NCT04525781 | Unknown status | Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer | October 2020 | December 2021 | |
| NCT04718948 | Unknown status | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine | January 28, 2021 | January 25, 2024 | |
| NCT05335707 | Withdrawn | Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy | September 14, 2022 | August 21, 2023 |
- Disase is a (Disease Ontology)
- DOID:3996
- Cross Reference ID (Disease Ontology)
- GARD:12210
- Cross Reference ID (Disease Ontology)
- ICD10CM:C67
- Cross Reference ID (Disease Ontology)
- ICD9CM:188
- Cross Reference ID (Disease Ontology)
- KEGG:05219
- Cross Reference ID (Disease Ontology)
- MESH:D001749
- Cross Reference ID (Disease Ontology)
- MIM:109800
- Cross Reference ID (Disease Ontology)
- NCI:C2901
- Cross Reference ID (Disease Ontology)
- NCI:C9334
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:126885006
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:363455001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0005684
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0005695
- Exact Synonym (Disease Ontology)
- bladder cancer
- Exact Synonym (Disease Ontology)
- tumor of the bladder